Skip to main content
. Author manuscript; available in PMC: 2017 Oct 18.
Published in final edited form as: JACC Basic Transl Sci. 2017 Apr 24;2(2):212–226. doi: 10.1016/j.jacbts.2016.11.008

Figure 1. Design variables to be considered when developing biomaterial applications for myocardial infarction (MI) and peripheral artery disease (PAD).

Figure 1

To successfully translate biomaterials to the clinic, specific design criteria must be considered to ensure the final product remains biocompatible while maintaining its full therapeutic efficacy. Extensive engineering of a biomaterial can maximize therapeutic benefits, but these benefits must counterbalance accompanied costs and manufacturing difficulties.